Education
About Us
Working with TipRanks
Follow Us
Regeneus Ltd. (AU:CMB)
ASX:CMB
CMB Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.19 - AU$0.68
Previous CloseN/A
Volume21.69K
Average Volume (3M)10.65K
Market Cap
AU$4.94M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)1.54M
Price to Earnings (P/E)―
Beta-8.23
Next Earnings
Feb 27, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding18,282,665
10 Day Avg. Volume20,391
30 Day Avg. Volume10,647
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Regeneus Ltd. News
PremiumCompany Announcements
Cambium Bio Advances Elate Ocular® to Phase 3 Trials After FDA Clearance
PremiumCompany Announcements
Cambium Bio Secures Ethics Approvals for Phase 3 Trials of Elate Ocular®
PremiumCompany Announcements
Cambium Bio Limited Announces Change of AddressPremiumCompany Announcements
Cambium Bio Limited Appoints New Director to Strengthen Leadership
PremiumCompany Announcements
Regeneus Ltd. Announces Director Departure and Shareholding DetailsPremiumCompany Announcements
Cambium Bio Limited Announces Leadership and Governance ChangesPremiumCompany Announcements
Cambium Bio Limited Announces Change in Registry AddressOptions Prices
Currently, No data available
---
Ownership Overview
41.36% Insiders
―
Mutual Funds
― Other Institutional Investors
58.64% Public Companies and
Individual Investors
CMB FAQ
What was Regeneus Ltd.’s price range in the past 12 months?
Regeneus Ltd. lowest share price was AU$0.19 and its highest was AU$0.68 in the past 12 months.
What is Regeneus Ltd.’s market cap?
Regeneus Ltd.’s market cap is AU$4.94M.
When is Regeneus Ltd.’s upcoming earnings report date?
Regeneus Ltd.’s upcoming earnings report date is Feb 27, 2025 which is 142 days ago.
How were Regeneus Ltd.’s earnings last quarter?
Currently, no data Available
Is Regeneus Ltd. overvalued?
According to Wall Street analysts Regeneus Ltd.’s price is currently Overvalued.
Does Regeneus Ltd. pay dividends?
Regeneus Ltd. does not currently pay dividends.
What is Regeneus Ltd.’s EPS estimate?
Regeneus Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Regeneus Ltd. have?
Regeneus Ltd. has 18,282,665 shares outstanding.
What happened to Regeneus Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Regeneus Ltd.?
Currently, no hedge funds are holding shares in AU:CMB
Regeneus Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:CMB Sentiment 100%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.50%
12-Months-Change
Fundamentals
Return on Equity
-983.90%
Trailing 12-Months
Asset Growth
4030.28%
Trailing 12-Months
Company Description
Regeneus Ltd.
Regeneus Ltd clinical-stage regenerative medicine company. It mainly develops a portfolio of cell-based therapies to address significant unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology diseases. The company uses stem cell and immuno-oncology technologies to develop cell-based therapies. Its product pipeline consists of two platform technologies, Progenza and Sygenus, across three target therapeutic areas namely osteoarthritis, neuropathic pain, and skin wound healing.
Technical Analysis
Zelira Therapeutics
―
Invex Therapeutics Ltd.
―
AdAlta Ltd.
―
Bio-Gene Technology Ltd.
―
Hexima Ltd
―